Abstract
The University of Central Florida invention comprises new compounds and synthesis methods for a spermine prodrug designed to treat symptoms of a low spermine disorder. The invention provides a new potential therapy for Snyder Robinson Syndrome (SRS). Patients with SRS have little or no spermine synthase (SMS) enzyme activity and cannot effectively make spermine from spermidine. Spermine is one of the naturally occurring polyamines and plays important roles in maintaining cell health.
Publications
Development of a Redox-Sensitive Spermine Prodrug for the Potential Treatment of Snyder Robinson Syndrome, J Med Chem. 2021 Nov 11;64(21):15593-15607. doi: 10.1021/acs.jmedchem.1c00419. Epub 2021 Oct 25. PMID: 34695351; PMCID: PMC9115777.
Brochure
